Table 2.
Detection of i(12p) or additional copies of chromosome 12 without i(12p) by fluorescence in situ hybridization (FISH) in primary tumors and SMNs.
Case No. | Primary Testicular Tumor | Age at Initial Diagnosis | Primary Treatment | Age at SMN | Time to SMN (Yrs.) | SMN Histology | Metastatic Tumor | % i(12p) FISH Positive | # i(12p) Copies |
1 | Seminoma * | 51 | BEP | 57 | 6.5 | Unclassified sarcoma | RP | 56% | 1–2 |
2 | Seminoma | 31 | XRT | 54 | 22.0 | Colorectal | Liver | 68% | 1 |
3 | Seminoma | 28 | XRT, BEP, HDC + SCT | 34 | 5.9 | LMS | Gluteus | 64% | 1–2 |
4 | Seminoma | 53 | BEP | 56 | 3.1 | Urothelial | Bladder | 39% | 1 |
5 | Nonseminoma | 39 | BEP | 39 | 0.4 | Pancreatic | Pancreas | 63% | 1–3 |
Case No. | Primary Histology | Age at Initial Diagnosis | Primary Treatment | Age at SMN | Time to SMN (Yrs.) | SMN Histology | Site of SMN | % Extra Copies Chromosome 12 | # i(12p) Copies |
6 | Seminoma | 33 | XRT | 51 | 18.0 | LMS | RP | 73% | 0 |
7 | Seminoma | 51 | XRT | 59 | 7.6 | Rectal (adenocarcinoma) | Rectum | 55% | 0 |
8 | Seminoma | 58 | XRT | 71 | 13.3 | Colorectal | Cecum | 36% | 0 |
9 | Seminoma | 57 | XRT | 65 | 8.5 | Lung (adenocarcinoma) | Lung | 72% | 0 |
10 | Seminoma | 29 | XRT | 59 | 24.6 | Melanoma | Axillary lymph node | 83% | 0 |
Nonseminoma | 44 | BEP | |||||||
11 | Seminoma | 22 | XRT | 58 | 9.6 | LMS | RP | 72% | 0 |
12 | Nonseminoma | 28 | CISCA/VB | 45 | 36.3 | LMS | RP | 74% | 0 |
13 | Seminoma | 53 | XRT | 58 | 44.8 | Colorectal | Lung | 83% | 0 |
14 | Seminoma | 62 | 65 | 5.2 | Lung (squamous) | Lung | 61% | 0 | |
15 | Seminoma | 27 | XRT | 81 | 3.0 | Urothelial | Bladder | 66% | 0 |
16 | NA | 20 | XRT + VB | 57 | 53.6 | Adrenal Cortical Carcinoma | Adrenal | 89% | 0 |
17 | Seminoma | 31 | XRT | 61 | 36.6 | Bladder | Bladder | 82% | 0 |
18 | Seminoma | 29 | CTX/carboplatin | 49 | 29.9 | Urothelial | Renal pelvis | 51% | 0 |
19 | Seminoma | 47 | XRT | 65 | 20.3 | Renal cell carcinoma | Kidney | 57% | 0 |
20 | Seminoma | 29 | PVB | 54 | 19.4 | Urothelial | Bladder | 91% | 0 |
BEP: bleomycin, etoposide, cisplatin. XRT: radiation therapy. HDC + SCT: high-dose chemotherapy + stem-cell transplantation. CEB: carboplatin, etoposide, bleomycin. PVB: cisplatin, vinblastine, bleomycin. CISCA: cyclophosphamide, doxorubicin, cisplatin. VB: vinblastine, bleomycin. CTX: cyclophosphamide. LMS: leiomyosarcoma. RP: retroperitoneum. * Diagnosed by biopsy of retroperitoneal lymph node. Pathology of primary tumor not available.